<DOC>
	<DOCNO>NCT01677884</DOCNO>
	<brief_summary>The purpose study assess efficiency treatment base objective response rate ( RECIST 1.1 )</brief_summary>
	<brief_title>Intra-arterial Hepatic Bevacizumab Systemic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Liver metastases colon cancer rectal predominant ( histological evidence obtain primary tumor liver metastasis ) Isolated ( extrahepatic metastasis , primary tumor resect ) No access curative hepatectomy ( R0 resection foreseeable leave less 30 % residual nontumor liver normally vascularize ) , require complex hepatectomy , large ( 5 segment ) / risk ( class II CPP ) least one measurable RECIST ( &gt; 2 cm , &gt; 1 cm Computed tomography ( CT ) spiral ) Or extrahepatic disease small size potentially accessible resection ( one two lung metastasis , lymphadenopathy localize accessible curative resection ) colon rectal primary tumor : resect asymptomatic Progression first line chemotherapy treat metastatic disease , type treatment allow except intraarterial Bevacizumab Age &gt; 18 year &lt; 75 year Performance status WHO 0 1 Life expectancy &gt; 3 month Bilirubin &lt; 1.5 time upper limit normal ( N ) , ASAT ALAT &lt; 5N , creatinine &lt; 1.5 N neutrophil &gt; 1.5 x 10^9/L , platelet â‰¥100 x 10^9/L , hemoglobin &gt; 9g/dL . Patients may include even transfuse CT ( MRI ) reference measurement metastasis perform within 28 day first treatment cycle Information patient legal representative signing informed consent Affiliated social security system Symptomatic colon rectal primary tumor ( subocclusion , significant hemorrhage , major rectal syndrome ) Extrahepatic metastasis small size disease potentially accessible resection Grade 34 allergy one treatment compound Two line prior chemotherapy . One line allow metastatic disease must start 6 month completion adjuvant treatment . Participation within 30 day study another therapeutic trial experimental molecule Concomitant cancer systemic treatment use immunotherapy , chemotherapy hormone Symptomatic CHD myocardial infarction within 6 month prior entry study , cardiac arrhythmia uncontrolled despite treatment Uncontrolled hypertension ( blood pressure &gt; 150/100 mm Hg despite hypertensive treatment ) Heart Failure &gt; Grade II New York Heart Association ( NYHA ) ( class IIIIIIV ) severe renal failure History / presence bleed disorder and/or thrombotic &lt; 6 month Uncontrolled Serious illness , uncontrolled active infection serious underlying condition may prevent patient receive treatment Pregnancy ( positive pregnancy test baseline ) , lactation contraception effective men woman childbearing age Occlusion subbowel obstruction history inflammatory bowel disease Other cancer within 5 year prior entry trial concomitant ( except situ cancer cervix skin basalcell carcinoma properly treat ) Legal inability ( person deprive liberty guardianship ) Inability sign consent submit medical test geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>